Company Product Description Indication Status
Phase I
Hutchison China Meditech Ltd., of Hong Kong HMPL-306 Selective small-molecule inhibitor of IDH1/2 Relapsed or refractory hematological malignancies Dosed first patient; study enrolling patients whose disease has IDH1 and/or IDH2 mutation
Noxxon Pharma NV, of Berlin NOX-A12 Stromal cell-derived factor 1 ligand inhibitor Newly diagnosed brain cancer Data safety monitoring board analyzed data from initial 4 weeks of first patient in second dose cohort testing combination with radiotherapy, concluding it is safe and appropriate to continue recruitment of additional patients according to protocol
Polarityte Inc., of Salt Lake City Skinte Autologous cell therapy Diabetic foot ulcers Interim analysis from first 50 patients showed 72% of patients in Skinte plus standard of care (SOC) group achieved wound closure by 12 weeks vs. 32% with SOC alone (p=0.005)
Phase II
Cytomx Therapeutics Inc., of South San Francisco CX-72 Probody therapeutic targeting PD-L1 Solid tumors Study testing combination with other cancer therapy terminated at sponsor’s decision
Theratechnologies Inc., of Montreal Tesamorelin GHRH receptor agonist HIV-associated nonalcoholic steatohepatitis Data published in JCI Insight from a subanalysis testing the drug’s effect on transcriptome of liver biopsies demonstrated tesamorelin had a positive effect on gene expression related to oxidative phosphorylation and decreased gene expression related to inflammation, tissue repair and cell division; treatment also led to improvement of genes associated with favorable hepatocellular carcinoma prognosis
Phase III
Alector Inc., of South San Francisco AL-001 Monoclonal antibody designed to modulate progranulin Frontotemporal dementia Dosed first patient in pivotal Infront-3 trial testing drug in people at risk for or with FTD due to a progranulin gene mutation
Northwest Biotherapeutics Inc., of Bethesda, Md. Dcvax-L Personalized immune therapy Glioblastoma Data collection from all sites completed; company anticipates remaining analyses, which have been affected by the COVID-19 pandemic, will be completed within next couple of weeks, after which overall trial dataset will be locked; trial results anticipated for reporting sometime in September 2020
UCB SA, of Brussels Bimekizumab IL-17A and IL-17F inhibitor Moderate to severe plaque psoriasis Results from phase IIIb Be Radiant head-to-head study with Cosentyx (secukinumab, Novartis AG) demonstrated superiority of bimekizumab for complete skin clearance at both weeks 16 and 48, as measured by a 100% improvement in the Psoriasis Area and Severity Index
Phase IV
Amgen Inc., of Thousand Oaks, Calif. Evolocumab Antibody targeting PCSK9 Familial hypercholesterolemia Study assessing drug’s impact on lowering platelet activation in FH patients terminated prematurely due to COVID-19

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments